• Skip to Content
• Skip to Navigation
• Skip to Utility Navigation
• Skip to Search

Plasma HIV RNA CD4 cell count Indinavir oral monotherapy phase I/II trials, 400 to 600 mg four times daily 1- to 2-log reduction after a few weeks of treatment; returned to baseline after 12 to 24 weeks 80- to 140-cell increases after a few weeks of treatment

Indinavir side effects: Dose-related hyperbilirubinemia in 15% of treated patients, and nephrolithiasis; generally well tolerated.Indinavir resistance: Appearance of viral strains with drug resistance seen in the majority of patients after a few weeks.